Answers are grounded in this paper and cite their sources.
Multicenter retrospective study demonstrates a 56.6% reduction in annual episodes with intranasal azelastine in recurrent acute rhinosinusitis, supporting prospective trials.
KEY POINTS: Self-controlled analysis: mean episodes reduced from 2.72 to 1.18 per year; 56.6% reduction. Treatment effect consistent across subgroups, from patients using intranasal corticosteroids (ICS) to those with concurrent chronicc rhinosinusitis (CRS). Findings support prospective randomized controlled trial evaluation of azelastine for recurrent acute rhinosinusitis (RARS).
No takes yet. Share an insight, caveat, or question.
Prabhakar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: